Parkinson’s Disease Treatment Market

The global Parkinson’s Disease Treatment Market is valued at USD 6.67 Billion in 2024 and is projected to reach a value of USD 19.24 Billion by 2035 at a CAGR (Compound Annual Growth Rate) of 10.1% between 2025 and 2035. The Parkinson’s Disease Treatment market industry is driven by the high prevalence of Parkinson’s Disease (PD) in Western nations, and a robust pipeline of disease-modifying treatments, growing elderly population, which faces a significant risk of developing Parkinson’s Disease.

Key Highlights

• Based on the Drug Class, the Carbidopa-levodopa category accounted for significant market share in Parkinson’s Disease Treatment market industry for 23.7% in 2024
• In 2024, by Distribution Channel, Retail Pharmacy dominated the Parkinson’s Disease Treatment market share of 60.1%
• North America dominated the Parkinson’s Disease Treatment market industry with 38.3% Parkinson’s Disease Treatment market share in 2024
• Asia Pacific region is anticipated to grow at the highest CAGR during the forecast period in Parkinson’s Disease Treatment market industry

Drug Class Overview

​The Drug Class segment is divided into Carbidopa-levodopa, Dopamine Agonists, MAO-B Inhibitors, COMT Inhibitors, Anticholinergics, Others. The Carbidopa-levodopa segment held the Parkinson’s Disease Treatment market size of 23.7% in 2024.

The Carbidopa-Levodopa drug class led the Parkinson’s Disease Treatment market industry in 2024, capturing over 23.7% of revenue due to the high prescription rate of these medications. According to U.S. Drug Use Statistics, there were approximately 527,530 Carbidopa-Levodopa prescriptions written for 183,690 Parkinson’s patients in 2020. This combination of Carbidopa and Levodopa is highly effective in managing Parkinson’s symptoms and is widely regarded as the most potent medication for the condition, typically used as a second-line treatment. It is primarily administered orally in various forms, including immediate-release tablets, controlled-release tablets, enteral suspension, and extended-release capsules.

The development of pipeline candidates like LY03003 and increasing demand for dopamine agonists are anticipated to support segment growth in Parkinson’s Disease Treatment market industry. The American Parkinson’s Disease Association (APDA) notes that there are currently four FDA-approved dopamine agonists in the U.S.: Requip (ropinirole), Mirapex (pramipexole), Apokyn (apomorphine), and Neupro (rotigotine). Ropinirole and Pramipexole are available in both regular and long-acting formulations, while Apomorphine is an injectable rescue medication that acts within 10 minutes. The approval of innovative treatments for Parkinson’s Disease is expected to further drive growth in Parkinson’s Disease Treatment market industry.

Distribution Channel Overview

​The Distribution Channel segment is divided into Hospital Pharmacy, Retail Pharmacy, Online Pharmacy. The Retail Pharmacy segment held the dominant share in 2024, accounting for significant Parkinson’s Disease Treatment industry share of 60.1%.

The retail pharmacy segment led the global Parkinson’s Disease Treatment industry in 2024 and expected to grow at the fastest rate in the coming years. According to Parkinson’s News, the prevalence of Parkinson’s Disease (PD) increases with age, affecting approximately 41 individuals per 100,000 in their 40s and over 1,900 per 100,000 in their 80s and 90s. As the second most common neurodegenerative disorder after Alzheimer’s, PD requires lifelong medication management, with retail pharmacies playing a key role in dispensing these treatments.

The widespread availability of PD drugs, including generic options like carbidopa-levodopa, pramipexole dihydrochloride, and selegiline hydrochloride, at retail pharmacy chains such as Walgreens and Walmart, further supports this segment’s dominance. Meanwhile, the online pharmacy segment is also poised for significant growth, fueled by the increasing popularity of online shopping, which offers convenience, flexibility, and cost savings. Discounts and promotional offers available on online platforms attract customers, contributing to the rising demand for online pharmacies and driving Parkinson’s Disease Treatment industry growth.

Regional Overview

In 2024, the Parkinson’s Disease Treatment market size of the North America is USD 2.55 Billion

North America Parkinson’s Disease Treatment industry report is driven by the presence of major companies like AbbVie Inc., Merck & Co. Inc., Amneal Pharmaceuticals LLC, and Sunovion Pharmaceuticals Inc. These key players contribute to growth by launching new products for managing Parkinsons disease (PD) symptoms. For example, in Sunovion Pharmaceuticals Inc. received U.S. FDA approval for Kynmobi, a treatment for off-episodes in PD patients. Additionally, ongoing and extensive research in the field of PD within the region is expected to further boost Parkinson’s Disease Treatment market growth.

In Canada, for instance, BlueRock Therapeutics administered the first dose of DA01 (dopaminergic neurons) to patients with advanced Parkinsons disease (PD) in January 2022. The successful completion of the trial and potential approval of the product are expected to drive Parkinson’s Disease Treatment market analysis in the region over the forecast period.

Asia Pacific Parkinson’s Disease Treatment Market

The Asia Pacific Parkinson’s Disease Treatment industry report is set for significant growth with over the forecast period fueled by increased product penetration, untapped market potential, and the rising prevalence of PD in developing countries. A case in point is UCB S.A., which received an Import Drug License (IDL) from the China Food and Drug Administration (CFDA) in July 2022 for the supply of Neupro in China. Neupro is recommended as a monotherapy or in combination with levodopa for treating early-stage idiopathic PD.

Europe Parkinson’s Disease Treatment Market

Europe are expected to see Parkinson’s Disease Treatment industry growth during the forecast period driven by increasing prevalence of Parkinson’s disease, a rising aging population, and advancements in treatment options. The Parkinson’s Disease Treatment market analysis is driven by the introduction of new therapies, such as innovative dopamine agonists and disease-modifying drugs, alongside strong research and development activities within the region. Furthermore, the presence of leading pharmaceutical companies and healthcare infrastructure, along with improved access to treatments, is anticipated to fuel Parkinson’s Disease Treatment market trend.

Based on the provided market data, Vantage Market Research offers customizations in the reports to meet the specific needs of clients.

Parkinson’s Disease Treatment Market Trends

• Advancements in Precision Medicine: Increased focus on personalized medicine, leveraging biomarkers and genetic insights to tailor treatment plans for better efficacy and reduced side effects
• Innovative Drug Delivery Systems: Introduction of technologies like continuous subcutaneous infusion (e.g., AbbVie’s VYALEV) and extended-release formulations to improve patient compliance and treatment outcomes
• Development of Disease-Modifying Therapies: Research targeting the underlying causes of Parkinson’s, such as alpha-synuclein aggregation inhibitors and gene therapies, is gaining momentum
• Integration of Diagnostics with Treatment: Breakthrough diagnostic tools, like Sunbird Bios alpha-synuclein protein detection, are enabling earlier and more accurate diagnosis, paving the way for timely intervention
• Rising Use of Digital Health Solutions: Wearable devices and mobile apps are being adopted for real-time monitoring of symptoms, medication adherence, and patient outcomes, enhancing overall disease management
• Expanding Access to Advanced Therapies: Emerging markets are increasingly adopting advanced Parkinsons treatments due to improved healthcare infrastructure and growing awareness, broadening the global Parkinson’s Disease Treatment market trend

Track market trends LIVE & outsmart rivals with our Premium Data Intel Tool: Vantage Point

Market Dynamics

Market Drivers for Parkinson’s Disease Treatment Market

Advancements in Treatment Options:

The treatment landscape for Parkinson’s disease (PD) is evolving with the development of novel therapies that aim to improve patient outcomes. Traditional treatments, such as Carbidopa-Levodopa, primarily focus on symptom management rather than slowing disease progression. However, disease-modifying therapies are emerging, aiming to address the root causes of PD, such as the accumulation of alpha-synuclein proteins in the brain. These innovative therapies, along with new drug delivery systems like continuous infusion therapies or extended-release formulations, are providing more effective and sustained symptom control. This progression in treatments is expanding Parkinson’s Disease Treatment market trend, as patients and healthcare providers seek advanced solutions for better quality of life and long-term management of the disease. The availability of these more effective therapies is expected to significantly increase patient access to advanced care and contribute to the overall Parkinson’s Disease Treatment market trend.

Market Restraints for Parkinson’s Disease Treatment market

High Treatment Costs:

Parkinson’s disease is a chronic and progressive condition, requiring lifelong treatment and regular healthcare interventions. The costs associated with managing PD, which include prescription drugs, physical therapy, hospitalizations, and long-term care services, can be substantial. For example, the cost of medications, diagnostic tests, rehabilitation services, and regular doctor visits can place a heavy financial burden on patients, especially in the case of elderly individuals who may already face limited financial resources. In regions with less access to healthcare insurance or reimbursement programs, the affordability of treatments becomes a significant barrier, limiting the number of patients who can access the best possible care. High treatment costs, especially for new and innovative therapies, may hinder market growth by limiting access to those who need it most.

Side Effects and Safety Concerns:

While many Parkinson’s treatments are effective in managing symptoms, they often come with side effects, especially with long-term use. For example, Carbidopa-Levodopa, a primary treatment, can cause motor fluctuations (such as involuntary movements) or other complications after extended use. Additionally, drugs like dopamine agonists and MAO-B inhibitors may have adverse effects like hallucinations, sleep disturbances, or nausea. These side effects can negatively affect patient quality of life and lead to medication non-compliance. The risk of adverse effects can also make clinicians hesitant to prescribe certain treatments, limiting their use and potentially slowing down the adoption of newer therapies. These safety concerns can also delay the approval of novel therapies, making it more challenging to bring innovative treatments to Parkinson’s Disease Treatment market.

Market Opportunities for Parkinson’s Disease Treatment market

Gene Therapy and Personalized Medicine:

Gene therapy and personalized medicine are rapidly emerging as transformative approaches to treating Parkinson’s disease in Parkinson’s Disease Treatment market. Gene therapy involves delivering specific genes into a patient’s cells to correct or replace faulty genes that contribute to the disease, potentially modifying the disease’s course. This approach is particularly exciting for PD, as it targets the underlying mechanisms of the disease rather than just alleviating symptoms. Personalized medicine tailors’ treatments to individual patients based on their genetic makeup, lifestyle, and other factors, ensuring more effective and less risky treatments. These advancements offer significant growth potential for the Parkinson’s Disease Treatment market, as they promise to improve treatment efficacy, minimize side effects, and provide more targeted interventions for specific patient populations.

Competitive Landscape

The Parkinson’s Disease Treatment market industry report is characterized by intense competition among key players focusing on innovative therapies to address unmet clinical needs. Major pharmaceutical companies such as AbbVie, Roche, and Novartis are driving advancements through novel drug formulations, including levodopa-based therapies and disease-modifying agents. Recent approvals, such as AbbVies VYALEV for continuous subcutaneous infusion, highlight the push toward patient-centric solutions. Emerging biotech firms like Sunbird Bio are also contributing to the competitive landscape with breakthrough diagnostic tools that enhance early detection and personalized treatment strategies.

The key players in the global Parkinson’s Disease Treatment market report include - Cerevel Therapeutics among others.

Recent Market Developments

Sunbird Bio Unveils Diagnostic Breakthrough for Parkinsons Disease with 86% Accuracy

• In November 2024, Sunbird Bio unveiled new findings demonstrating that its diagnostic technology achieved an 86% accuracy rate in classifying blood samples from patients with Parkinsons disease by directly detecting aggregated alpha-synuclein proteins

AbbVies VYALEV Gains FDA Approval as First 24-Hour Levodopa Infusion Therapy for Parkinsons

• In October 2024, AbbVie announced FDA approval for VYALEV (foscarbidopa/foslevodopa), a groundbreaking treatment for motor fluctuations in adults with advanced Parkinsons disease. This therapy is the first of its kind to provide a 24-hour continuous subcutaneous infusion of a levodopa-based medication

The global Parkinson’s Disease Treatment market can be categorized as Drug Class, Distribution Channel and Region.